TRACT Therapeutics and Taiwan Bio Therapeutics Announce Poster Presentation at American Transplant Congress 2024

CHICAGO & TAIPEI, Taiwan–(BUSINESS WIRE)–TRACT Therapeutics and Taiwan Bio Therapeutics are pleased to announce a poster presentation at the 2024 annual meeting of the American Transplant Congress (ATC) taking place June 1-5, 2024, in Philadelphia, PA. TRACT Therapeutics, a clinical-stage biotechnology company, and Taiwan Bio Therapeutics, a world-class expert in cell therapy manufacturing, formed a strategic partnership in Nov 2023 to advance a novel regulatory T cell (Treg) therapy approach to preventing rejection in solid organ transplants. Together, the companies will launch a Phase 2 clinical trial investigating the ability of Treg therapy to reduce the use of immunosuppressant drugs in living donor kidney transplant recipients. Research centers will be located in the United States and Taiwan.

Joseph R Leventhal, MD, PhD, Fowler McCormick Professor of Surgery at Northwestern University and Scientific Founder of TRACT Therapeutics stated, “Developing more effective treatments for patients facing an organ transplant is a pressing need and the ATC provides a dynamic platform for professionals to exchange insights on their work and experiences in the field of transplantation medicine. TRACT’s regulatory T cell therapy has the potential to make a significant impact on treatment paradigms, improving patient outcomes and quality of life, and we look forward to sharing our Phase 2 trial design and methods at the conference.”

Details of the poster presentation are as follows:

Abstract Title: “A Phase 2 Study of Regulatory T Cell Therapy to Achieve Immunosuppression (IS) Reduction in Living Donor Kidney Transplant (LDKTx) Recipients: The RETIRE Trial”

Authors: J Leventhal, C Stratton, J Mathew, C Yang, S Murray

Category: Clinical Trials

About TRACT Therapeutics

TRACT Therapeutics, Inc. is a clinical stage biotechnology company developing a novel therapeutic approach to restoring immune balance in organ transplantation and autoimmune disease. Its proprietary platform technology, using autologous polyclonal expanded regulatory T cells, was developed at Northwestern University by pioneer, Joseph R Leventhal, MD, PhD, Fowler McCormick Professor of Surgery at Northwestern University, and his research colleagues. For additional information, visit our website at www.tracttherapeutics.com.

About Taiwan Bio Therapeutics

Taiwan Bio Therapeutics Co., Ltd. is a one-stop, total solution cell therapy CDMO focusing on accelerating the translation of early-stage cell therapies to clinical products. Its cell engineering and cGMP manufacturing technology platforms streamline “vein-to-vein” process design and allow thorough product characterization. Taiwan Bio is where cutting-edge science meets world-class manufacturing, helping innovators to convert their bench side discoveries into bed side therapies in record time. Discover more at: https://twbio-thera.com/language/en/about-us/.

This press release contains forward-looking statements that express the belief, potential anticipation, or expectation, as well as other statements which are not historical fact, and statements related to clinical trials and their results, design, FDA product approvals or other marketing approvals, features, functionality, and performance. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements.

Contacts

For media inquiries, please contact:

Lisa Juang, Lisa.Juang@twbio-thera.com, +886-2-26956382